SCHEMBL18797473

SCHEMBL18797473

Oc1cc(Cl)ccc1-c1cnn(C(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FPR2 P25090 1/20 0.43
▸ PDE3B Q13370 4/20 0.40
▸ PDE3A Q14432 4/20 0.40
▸ F11 P03951 5/20 0.39
▸ KLKB1 P03952 4/20 0.39
▸ SCN9A Q15858 1/20 0.38
▸ KCNH2 Q12809 1/20 0.37
▸ NTRK1 P04629 2/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ RRM1 P23921 1/20 0.36
▸ RRM2B Q7LG56 1/20 0.36
▸ CCNC P24863 1/20 0.36
▸ CDK8 P49336 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ GRM2 Q14416 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30702150 0.84 FPR2 (0.40) FPR2PDE3BPDE3AF11KLKB1
SCHEMBL20360209 0.84 FPR2 (0.40) FPR2PDE3BPDE3AF11KLKB1
SCHEMBL16983106 0.84 FPR2 (0.40) FPR2PDE3BPDE3AF11KLKB1
SCHEMBL17661863 0.81 PDE3B (0.42) FPR2PDE3BPDE3AF11KLKB1
SCHEMBL24785961 0.76 PDE3B (0.39) FPR2PDE3BPDE3AF11KLKB1
SCHEMBL21901531 0.75 GRM5 (0.39) FPR2PDE3BPDE3AF11KLKB1
SCHEMBL29780104 0.73 CHRM1 (0.41) FPR2PDE3BPDE3AF11KLKB1
SCHEMBL18797533 0.73 CHRM1 (0.41) FPR2PDE3BPDE3AF11KLKB1
SCHEMBL30271805 0.73 FPR2 (0.35) FPR2PDE3BPDE3AF11KLKB1
SCHEMBL29156776 0.72 KCNH2 (0.35) FPR2PDE3BPDE3AF11KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3368036-B1 MACROCYCLIC PYRIDINE-N-OXIDE DERIVATIVES AS FACTOR XIA INHIBITORS MERCK SHARP & DOHME LLC (US) 2022-07-20 — — EP disclosed
US-20180339977-A1 FACTOR XIA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-11-29 — — US disclosed
EP-3368036-A1 FACTOR XIA INHIBITORS Merck Sharp & Dohme Corp. (US) 2018-09-05 — — EP disclosed
WO-2017074832-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339977-A1 FACTOR XIA INHIBITORS F11, SERPINC1, TFPI FPR2 1058/4885PDE3B 1438/4885PDE3A 1844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback